Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-06-03

Clinical Trial Update: Safety and Efficacy of Furosemide 40mg + Amiloride Hydrochloride 10mg to Reduct Edema [Phase 3]

View source ↗

Summary

Phase 3 trial updating safety and efficacy of furosemide 40mg plus amiloride hydrochloride 10mg for edema reduction in congestive heart failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AMILORIDE HYDROCHLORIDE (AMILORIDE HYDROCHLORIDE)
  • FUROSEMIDE (Furosemide)

Snippet

Sponsor: Eurofarma Laboratorios S.A. | Conditions: Congestive Heart Failure | Phase 3 | Status: TERMINATED